Cantor Fitzgerald analyst Sarah James raised the firm’s price target on LifeMD to $15 from $13 and keeps an Overweight rating on the shares. Cantor doesn’t see a slowdown in LifeMD’s ability to grow the weight management business and is incrementally encouraged to see this record growth, complemented by investments into other areas of its business, and sees upside to increased revenue guidance, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD Welcomes Cardiology Expert Calum MacRae to Board
- LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-1 Patient Care with Real-time, At-Home Monitoring of Blood Pressure and Body Composition
- LifeMD enters strategic partnership with Withings Heath Solutions
- LifeMD management to meet with BTIG
- LifeMD appoints MacRae to board of directors